Autolus Therapeutics plc (AUTL) Stock

Autolus Therapeutics plc, headquartered in London, United Kingdom, is a dynamic clinical-stage biopharmaceutical company dedicated to advancing innovative T cell therapies for the treatment of cancer. The company's robust pipeline includes several promising programs aimed at harnessing the power of programmed T cells to target various cancers effectively.

Among its clinical-stage programs, Autolus Therapeutics is advancing obecabtagene autoleucel (AUTO1), a CD19-targeting T cell therapy currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in Phase 1 trials for pediatric patients with relapsed or refractory ALL. The company's portfolio also features AUTO4, designed for peripheral T-cell lymphoma, AUTO6NG targeting GD2 for neuroblastoma in preclinical trials, and AUTO8 undergoing Phase I trials for multiple myeloma. Autolus Therapeutics is also actively developing AUTO5, a hematological product candidate in preclinical stages.

Founded in 2014, Autolus Therapeutics has rapidly emerged as a leader in the field of T cell therapies, leveraging cutting-edge research and strategic collaborations to advance its pipeline. With a steadfast commitment to transforming cancer treatment paradigms, the company continues to pioneer novel therapies that hold promise for improving outcomes and quality of life for patients worldwide.